Business ❯ Pharmaceuticals

Drug Development

Clinical Trials Weight Loss Drugs Obesity Treatments Market Competition Clinical Research Licensing Agreements Oncology Market Trends Artificial Intelligence Regulatory Affairs

Deloitte Warns GLP-1 Boom Is Inflating Pharma Returns, Concentrating Risk

Heavy bets on obesity drugs increase vulnerability to shocks.

Pfizer Settles With Three Generics to Keep Vyndamax Exclusive Until 2031

FDA Launches First Real-Time Clinical Trial Pilot With AstraZeneca and Amgen

Lilly and Profluent Strike AI Gene-Editing Pact Worth Up to $2.25 Billion

Boehringer Ingelheim to Invest £150 Million in London AI Drug Discovery Centre

OpenAI Launches GPT-Rosalind, a Biology-Tuned AI for Drug Discovery

Roche Starts Placebo-Controlled Phase 3 Trial of Elevidys to Pursue EU Approval

Novo Nordisk Partners With OpenAI to Speed Drug Development and Operations

Allogene Soars on Early ALPHA3 Readout Showing Strong MRD Edge and Clean Safety

IDEAYA Combo Doubles Progression-Free Survival in Uveal Melanoma Trial

JW Pharmaceutical Licenses Korean Rights to Gan & Lee’s GLP-1 Drug in Deal Worth Up to $81 Million

Lilly to Acquire Centessa for $6.3 Billion to Add Orexin Sleep Drugs

Lilly Strikes $2.75 Billion Deal for Insilico’s AI-Designed Oral Drugs

Summit Therapeutics Shares Rally as Ivonescimab Trials Near Q2 Readout

Pfizer, Valneva Seek Approval for Lyme Vaccine After >70% Efficacy in Phase 3

Elon Musk Unveils 'Terafab' Chip Complex in Texas for Tesla, SpaceX and xAI

Corcept Faces Securities Class Action Over Relacorilant Disclosures as Firms Rally Investors Before April 21 Deadline

Roche Expands NVIDIA Partnership, Building Pharma’s Largest Hybrid‑Cloud AI Factory

HSBC Cuts Eli Lilly to Reduce, Lowers Target to $850 on GLP-1 Reset

Roche Launches Nvidia-Powered AI Factory With 2,176 New Blackwell GPUs, Claims Pharma’s Largest Footprint